Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease

Author： Yu Andrew P.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.7, 2009-07, pp. : 609-621

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Scheduled infliximab maintenance worthy for Crohn's disease in UK

By  

Inpharma, Vol. 1, Iss. 1650, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Infliximab maintenance therapy valuable strategy in Crohn's disease.

By  

Inpharma, Vol. 1, Iss. 1313, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Infliximab improves QOL in active and fistulising Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1346, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Treatment of Advanced Parkinson's Disease in the United States: A Cost-Utility Model

By Groenendaal Huybert  

Clinical Drug Investigation, Vol. 30, Iss. 11, 2010-11 ,pp. : 789-798

Adis International

Access to resources Recommend Favorite

Economic Implications of Biological Therapies for Crohn’s Disease: Review of Infliximab

By Bodger Keith  

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 875-888

Adis International

Access to resources Recommend Favorite